The Europe Gabapentin Market would witness market growth of 4.0% CAGR during the forecast period (2022-2028).
A persistent brain disorder that is not contagious. It is characterized by recurring seizures, which are brief bursts of uncontrollable movement that can affect either a small portion of the body or the entire body. Approximately, 4-10 per 1000 people are thought to be affected by active epilepsy, which is defined as having ongoing seizures or requiring treatment at any given moment in the general population. Each year, epilepsy is thought to affect 5 million people. According to estimates, epilepsy affects 49 of every 100,000 people in high-income nations.
This number can reach 139 per 100,000 in underdeveloped nations. This is probably caused by the increased risk of endemic diseases like neurocysticercosis or malaria, the increased frequency of birth-related injuries and injuries from motor vehicle accidents, as well as variations in the medical facilities, the provision of preventive health programs, and access to care. People with epilepsy comprise over 80% of the population in underdeveloped nations. As a result, epilepsy is one of the problems that are being treated with the use of gabapentin.
Sleep disorders are increasing in the region. Germany had a 4% prevalence of severe insomnia, lower than the 6-22% in other European nations. Most individuals have persistent symptoms, with many having significant sleep issues for over a year. Severe insomniacs have higher rates of visits to family doctors, prescription drug use, diagnostic tests, and hospitalization. As a result, many regional governments have increased their healthcare expenditures to lessen the burden of health issues like insomnia and chronic pain. Hence, the requirement for drugs to treat sleep disorders, chronic pain, and other problems are increasing the demand for gabapentin, which is advancing the market's growth.
The Germany market dominated the Europe Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $168.8 million by 2028. The UK market is anticipated to grow at a CAGR of 3.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 4.8% during (2022 - 2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Gabapentin Market is Projected to reach USD 2.6 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Epilepsy
- Restless Legs Syndrome
- Neuropathic Pain
- Others
By Dosage Form
- Capsule
- Tablet
- Oral Solution
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Gabapentin Market, by Application
1.4.2 Europe Gabapentin Market, by Dosage Form
1.4.3 Europe Gabapentin Market, by Distribution Channel
1.4.4 Europe Gabapentin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Gabapentin Market by Application
3.1 Europe Epilepsy Market by Country
3.2 Europe Restless Legs Syndrome Market by Country
3.3 Europe Neuropathic Pain Market by Country
3.4 Europe Others Market by Country
Chapter 4. Europe Gabapentin Market by Dosage Form
4.1 Europe Capsule Market by Country
4.2 Europe Tablet Market by Country
4.3 Europe Oral Solution Market by Country
Chapter 5. Europe Gabapentin Market by Distribution Channel
5.1 Europe Hospital Pharmacy Market by Country
5.2 Europe Retail Pharmacy Market by Country
5.3 Europe Online Pharmacy Market by Country
Chapter 6. Europe Gabapentin Market by Country
6.1 Germany Gabapentin Market
6.1.1 Germany Gabapentin Market by Application
6.1.2 Germany Gabapentin Market by Dosage Form
6.1.3 Germany Gabapentin Market by Distribution Channel
6.2 UK Gabapentin Market
6.2.1 UK Gabapentin Market by Application
6.2.2 UK Gabapentin Market by Dosage Form
6.2.3 UK Gabapentin Market by Distribution Channel
6.3 France Gabapentin Market
6.3.1 France Gabapentin Market by Application
6.3.2 France Gabapentin Market by Dosage Form
6.3.3 France Gabapentin Market by Distribution Channel
6.4 Russia Gabapentin Market
6.4.1 Russia Gabapentin Market by Application
6.4.2 Russia Gabapentin Market by Dosage Form
6.4.3 Russia Gabapentin Market by Distribution Channel
6.5 Spain Gabapentin Market
6.5.1 Spain Gabapentin Market by Application
6.5.2 Spain Gabapentin Market by Dosage Form
6.5.3 Spain Gabapentin Market by Distribution Channel
6.6 Italy Gabapentin Market
6.6.1 Italy Gabapentin Market by Application
6.6.2 Italy Gabapentin Market by Dosage Form
6.6.3 Italy Gabapentin Market by Distribution Channel
6.7 Rest of Europe Gabapentin Market
6.7.1 Rest of Europe Gabapentin Market by Application
6.7.2 Rest of Europe Gabapentin Market by Dosage Form
6.7.3 Rest of Europe Gabapentin Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Zydus Lifesciences Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Trials and approvals:
7.2 Glenmark Pharmaceuticals Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expense
7.4 Sun Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and Mergers:
7.5 Alkem Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 Aurobindo Pharma Limited
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 Amneal Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expenses
7.9 Cipla Limited
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Apotex, Inc.
7.10.1 Company Overview
TABLE 1 Europe Gabapentin Market, 2018 - 2021, USD Million
TABLE 2 Europe Gabapentin Market, 2022 - 2028, USD Million
TABLE 3 Europe Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 4 Europe Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 5 Europe Epilepsy Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Epilepsy Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Restless Legs Syndrome Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Restless Legs Syndrome Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Neuropathic Pain Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Neuropathic Pain Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 14 Europe Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 15 Europe Capsule Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Capsule Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Tablet Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Tablet Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Oral Solution Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Oral Solution Market by Country, 2022 - 2028, USD Million
TABLE 21 Europe Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 22 Europe Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 23 Europe Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 25 Europe Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 26 Europe Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 27 Europe Online Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 28 Europe Online Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 29 Europe Gabapentin Market by Country, 2018 - 2021, USD Million
TABLE 30 Europe Gabapentin Market by Country, 2022 - 2028, USD Million
TABLE 31 Germany Gabapentin Market, 2018 - 2021, USD Million
TABLE 32 Germany Gabapentin Market, 2022 - 2028, USD Million
TABLE 33 Germany Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 34 Germany Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 35 Germany Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 36 Germany Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 37 Germany Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 38 Germany Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 39 UK Gabapentin Market, 2018 - 2021, USD Million
TABLE 40 UK Gabapentin Market, 2022 - 2028, USD Million
TABLE 41 UK Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 42 UK Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 43 UK Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 44 UK Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 45 UK Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 46 UK Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 47 France Gabapentin Market, 2018 - 2021, USD Million
TABLE 48 France Gabapentin Market, 2022 - 2028, USD Million
TABLE 49 France Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 50 France Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 51 France Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 52 France Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 53 France Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 54 France Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 55 Russia Gabapentin Market, 2018 - 2021, USD Million
TABLE 56 Russia Gabapentin Market, 2022 - 2028, USD Million
TABLE 57 Russia Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 58 Russia Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 59 Russia Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 60 Russia Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 61 Russia Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 62 Russia Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 63 Spain Gabapentin Market, 2018 - 2021, USD Million
TABLE 64 Spain Gabapentin Market, 2022 - 2028, USD Million
TABLE 65 Spain Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 66 Spain Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 67 Spain Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 68 Spain Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 69 Spain Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 70 Spain Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 71 Italy Gabapentin Market, 2018 - 2021, USD Million
TABLE 72 Italy Gabapentin Market, 2022 - 2028, USD Million
TABLE 73 Italy Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 74 Italy Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 75 Italy Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 76 Italy Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 77 Italy Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 78 Italy Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 79 Rest of Europe Gabapentin Market, 2018 - 2021, USD Million
TABLE 80 Rest of Europe Gabapentin Market, 2022 - 2028, USD Million
TABLE 81 Rest of Europe Gabapentin Market by Application, 2018 - 2021, USD Million
TABLE 82 Rest of Europe Gabapentin Market by Application, 2022 - 2028, USD Million
TABLE 83 Rest of Europe Gabapentin Market by Dosage Form, 2018 - 2021, USD Million
TABLE 84 Rest of Europe Gabapentin Market by Dosage Form, 2022 - 2028, USD Million
TABLE 85 Rest of Europe Gabapentin Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 86 Rest of Europe Gabapentin Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 87 Key Information – Zydus Lifesciences Ltd.
TABLE 88 Key Information – Glenmark Pharmaceuticals Limited
TABLE 89 Key Information – Pfizer, Inc.
TABLE 90 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 91 Key Information – Alkem Laboratories Ltd.
TABLE 92 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 93 key information – Aurobindo Pharma Limited
TABLE 94 Key Information – Amneal Pharmaceuticals, INc.
TABLE 95 Key Information – Cipla Limited
TABLE 96 Key Information – Apotex, Inc.
List of Figures
FIG 1 Methodology for the research